MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV

Hepatitis C, Chronic Clinical Trial

Official title:

A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03003338
• Other study ID #: MHH-HCV-NPM
• Secondary ID: 2015-004556-22
• Status: Terminated
• Phase: Phase 4
• Start date: October 24, 2017
• Est. completion date: October 22, 2018

Study information

• Verified date: August 2023
• Source: Hannover Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 1:1 randomized double-blind Placebo-controlled moncenter Phase IV study to investigate whether a successful interferon-free treatment of HCV-infection with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in combination with dasabuvir (DSV) improves the patients' attention ability as compared to placebo as measured with the Att Test Sum Score change from baseline to week 12. A total of 30 patients with non-cirrhotic genotype 1b HCV infection will be randomly assigned to receive 12 weeks verum followed by 12 weeks Placebo (arm A) versus 12 weeks Placebo followed by 12 weeks verum (arm B). Patients will be followed up for 48 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: October 22, 2018
• Est. primary completion date: October 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent

2. Male or female, age =18 years

3. Chronic hepatitis C virus infection

4. Fatigue Impact Scale Score (FIS) >45 and a sum score (Att Test Sum Score) >0.4 in the battery of attention tests applied.

5. Female who is:

• practicing total abstinence from sexual intercourse (minimum 1 complete menstrual cycle)

• sexually active with female partners only

• not of childbearing potential, defined as:

• postmenopausal for at least 2 years (defined as amenorrheic for longer than 2 years, age appropriate, and confirmed by a follicle-stimulating hormone [FSH] level indicating a postmenopausal state), or

• surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or has a vasectomized partner (s);

• of childbearing potential and sexually active with male partner(s):

• currently using an effective method of birth control at the time of screening and

• agree to practice highly effective methods of birth control while receiving study drugs and at least one effective method of birth control during the follow-up period (see section 4.3). (Note: Ethinylestradiol-containing hormonal contraceptives, including oral, injectable, implantable, patch and ring varieties, may not be used during study drug treatment.)

6. Females of childbearing potential must have negative results for pregnancy tests performed:

• at Screening on a serum specimen obtained within 28 days prior to initial study drug administration, and

• on a urine sample obtained on Study Day 1 (prior to dosing).

7. Males who are not surgically sterile and who are sexually active with female partner(s) of childbearing potential must agree to practice an effective form of birth control (see section 4.3) throughout the course of the study, starting with Study Day 1 and for 30 days after stopping study drug.

8. Subject must be able to comply with the dosing instructions for study drug administration and be able to complete the study schedule of assessments.

9. Body Mass Index (BMI) is > 17 to < 40 kg/m2. BMI is calculated as weight measured in kg divided by the square of height measured in meters (m).

10. Confirmation of chronic genotype 1b HCV infection documented by the following:

Positive for anti-HCV antibody or HCV RNA at least 6 months before Screening, and positive for HCV RNA and anti-HCV antibody at the time of Screening

11. Per local standard practice, documented results of:

• Index (APRI) = 2 at Screening, or

• FibroScan® result of < 12 kPa at Screening or

• The absence of cirrhosis based on a liver biopsy within the last 36 months.

12. HCV > RNA 1000 IU/ml at Screening

13. Subject must be of generally good health as determined by the Investigator.

14. Subject has not been treated with any investigational drug or device or any commercially available anti-HCV agents within 42 days of the Screening visit.

Exclusion Criteria:

1. Any previous exposure to HCV protease inhibitors, HCV NS5A inhibitors or HCV polymerase inhibitors

2. History of severe, life threatening or other significant sensitivity to any drug.

3. Pregnant or nursing female or male with pregnant female partner

4. Recent (within 6-months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol.

5. Infection with hepatitis B virus (HBV; defined as HBsAg-positive) or human immunodeficiency virus (HIV)

6. Use of any medication that are contraindicated for use with OBV/PTV/r and DSV within 2 weeks prior to study drug administration or 10 half-lives of the medication whichever is longer (see SmPC of OBV/PTV/r and DSV and section 4.4).

7. Clinically-significant illness (other than HCV) or any other major medical disorder that, in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.

8. Positive result of a urine drug screen at the Screening Visit for opiates, barbiturates, amphetamines, cocaine, benzodiazepines, phencyclidine, and propoxyphene.

9. History of uncontrolled seizures, cancer (except basal cell carcinoma of the skin), or uncontrolled diabetes, as defined by a hemoglobin A1C level > 8.0% or other systemic diseases that affect directly the CNS and brain metabolites.

10. Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug (for example, gastric bypass or severe ulcerative colitis).

11. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, Wilson's disease, a1 antitrypsin deficiency, cholangitis)

12. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.

13. Clinical hepatic decompensation (i.e., clinical ascites, encephalopathy or variceal hemorrhage).

14. Solid organ transplantation.

15. Significant pulmonary disease or significant cardiac disease.

16. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

17. Contraindications for MRI study

18. Screening laboratory analyses show any of the following abnormal laboratory results:

• Alanine aminotransferase (ALT) > 10 × upper limit of normal (ULN)

• Aspartate aminotransferase (AST) > 10 × ULN

• Calculated creatinine clearance (using CKD-EPI equal) < 30 mL/min

• Albumin < lower limit of normal (LLN)

• INR > 1.5

• Hemoglobin < LLN

• Platelets < 90,000 cells per mm3

• Total bilirubin > 2.0 mg/dL

• HCV RNA levels that are above the upper level of assay quantification

19. Screening ECG with clinically significant abnormalities

20. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive the study medication

21. Donation or loss of more than 400 ml blood within 2 months prior to Baseline/Day 1

Related Conditions & MeSH terms

• Hepatitis C
• Hepatitis C, Chronic
• Infections

Intervention

Drug:
• OBV/PTV/r and DSV
OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
• Placebo to match OBV/PTV/r and DSV
Placebo to match OBV/PTV/r and DSV

Locations

Country	Name	City	State
Germany	Hannover Medical School	Hannover

Sponsors (2)

Lead Sponsor	Collaborator
Hannover Medical School	AbbVie

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	HCV-specific T cell responses	To assess any relationship between HCV-specific T cell responses and regulatory T cells	Baseline and 48 weeks follow-up
Other	HCV-specific T cell responses	To assess any relationship between HCV-specific T cell responses and neuropsychatric symptoms	Baseline and 48 weeks follow-up
Other	Relationship between NK cell phenotype and function	To assess any relationship between NK cell phenotype and function	Baseline and 48 weeks follow-up
Other	Relationship between NK cell phenotype and neuropsychatric symptoms	To assess any relationship between NK cell phenotype and neuropsychiatric symptoms	Baseline and 48 weeks follow-up
Other	Causality between microbiome composition of the gut and the stage of HCV infection/ liver disease in relation to neuropsychiatric findings	To assess causalities between the microbiome composition of the gut and the stage of HCV infection/ liver disease in relation to neuropsychiatric findings	Baseline and 48 weeks follow-up
Primary	Change in the Attention Test Battery Sum Score (Att Test Sum Score) at week 12 (12 weeks minus baseline)	To investigate whether a successful interferon-free treatment of HCV-infection with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in combination with dasabuvir (DSV) improves the patients' attention ability as compared to placebo as measured with the Att Test Sum Score change from baseline to week 12.	12 weeks
Secondary	Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU 12 after discontinuation of therapy	To investigate whether a treatment with OBV/PTV/r in combination with DSV for 12 wk in patients with chronic genotype 1b HCV infection is safe and effective in patients with chronic fatigue and impaired neuropsychiatric function	Baseline and FU12
Secondary	Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU 24 after discontinuation of therapy	To investigate whether a treatment with OBV/PTV/r in combination with DSV for 12 wk in patients with chronic genotype 1b HCV infection is safe and effective in patients with chronic fatigue and impaired neuropsychiatric function	Baseline and FU 24
Secondary	Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU48 after discontinuation of therapy	To investigate whether a treatment with OBV/PTV/r in combination with DSV for 12 wk in patients with chronic genotype 1b HCV infection is safe and effective in patients with chronic fatigue and impaired neuropsychiatric function	Baseline and FU 48
Secondary	Change in FIS at Treatment week 12 after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves FIS.	Baseline and week 12
Secondary	Change in FIS at Treatment at 12 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves FIS.	Baseline and 12 weeks of follow-up
Secondary	Change in FIS at Treatment at 24 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves FIS.	Baseline and 24 weeks of follow-up
Secondary	Change in FIS at Treatment at 48 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves FIS.	Baseline and 48 weeks of follow-up
Secondary	Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at Treatment week 12 after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) score.	Baseline and 12 weeks
Secondary	Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 12 weeks follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) score.	Baseline and 12 weeks follow-up
Secondary	Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 24 weeks follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) score.	Baseline and 24 weeks follow-up
Secondary	Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 48 weeks follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) score.	Baseline and 48 weeks follow-up
Secondary	Change in TAP Attention test scores at Treatment week 12 after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves TAP Attention test scores.	Baseline and 12 weeks
Secondary	Change in TAP Attention test scores at 12 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves TAP Attention test scores.	Baseline and 12 weeks follow-up
Secondary	Change in TAP Attention test scores at 24 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves TAP Attention test scores.	Baseline and 24 weeks follow-up
Secondary	Change in TAP Attention test scores at 48 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves TAP Attention test scores.	Baseline and 48 weeks follow-up
Secondary	Change in word-figure Memory test scores for verbal and figural Memory function at Treatment week 12 after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves word-figure Memory test scores for verbal and figural Memory function.	Baseline and 12 weeks
Secondary	Change in word-figure Memory test scores for verbal and figural Memory function at 12 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves word-figure Memory test scores for verbal and figural Memory function.	Baseline and 12 weeks follow-up
Secondary	Change in word-figure Memory test scores for verbal and figural Memory function at 24 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves word-figure Memory test scores for verbal and figural Memory function.	Baseline and 24 weeks follow-up
Secondary	Change in word-figure Memory test scores for verbal and figural Memory function at 48 weeks of follow-up after Treatment discontinuation	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves word-figure Memory test scores for verbal and figural Memory function.	Baseline and 48 weeks follow-up
Secondary	Change in brain metabolite Levels after anti-viral Treatment	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection results in changes of the cerebral metabolites N-acetyl-aspartate, total creatine, choline, Glutamin/Glutamate, and myo-inositol.	Baseline and 12 weeks
Secondary	Change in brain metabolite Levels after 12 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection results in changes of the cerebral metabolites N-acetyl-aspartate, total creatine, choline, Glutamin/Glutamate, and myo-inositol.	Baseline and 12 weeks follow-up
Secondary	Change in brain metabolite Levels after 24 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection results in changes of the cerebral metabolites N-acetyl-aspartate, total creatine, choline, Glutamin/Glutamate, and myo-inositol.	Baseline and 24 weeks follow-up
Secondary	Change in brain metabolite Levels after 48 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection results in changes of the cerebral metabolites N-acetyl-aspartate, total creatine, choline, Glutamin/Glutamate, and myo-inositol.	Baseline and 48 weeks follow-up
Secondary	Change in the patients mood at Treatment week 12	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves the patients mood as measured with the Hospital Anxiety and Depression Score.	Baseline and week 12
Secondary	Change in the patients mood at 12 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves the patients mood as measured with the Hospital Anxiety and Depression Score.	Baseline and 12 weeks follow-up
Secondary	Change in the patients mood at 24 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves the patients mood as measured with the Hospital Anxiety and Depression Score.	Baseline and 24 weeks follow-up
Secondary	Change in the patients mood at 48 weeks follow-up	To investigate whether treatment with OBV/PTV/r in combination with DSV for 12 weeks in patients with chronic genotype 1b HCV infection improves the patients mood as measured with the Hospital Anxiety and Depression Score.	Baseline and 24 weeks follow-up
Secondary	Change in the Att Test Sum Score at 12 weeks of follow-up		Baseline and 12 weeks follow-up
Secondary	Change in the Att Test Sum Score at 24 weeks of follow-up		Baseline and 24 weeks follow-up
Secondary	Change in the Att Test Sum Score at 48 weeks of follow-up		Baseline and 48 weeks follow-up